How To Keep Academic/Big Pharma Alliances from Going off the Rails


Xconomy San Diego — 

The Dana-Farber Cancer Institute in Boston made headlines earlier this month after siding with Novartis in a brewing legal battle with a Dana-Farber spinout, Gatekeeper Pharmaceuticals. The disagreement stems from both companies claiming they are the rightful licensees of certain intellectual property (IP) created by Dana-Farber researchers.

The IP, originally committed to Gatekeeper via an option agreement, was later determined to fall under a broad 2005 alliance with Novartis, which granted the pharma exclusive rights to certain Dana-Farber projects. This dispute over who controls the licensing rights to a potential cancer drug is sure to bring attention to the issues inherent in broad strategic alliances between academia and industry.

It’s common for companies to sponsor the work of an individual lab or to support a specific project, but these types of broad institutional strategic alliances that grant rights to wide areas of technology were once rare, even controversial. But they have been proliferating in recent years. Washington University in St. Louis (Pfizer), Cancer Research UK, the University of Pennsylvania (AstraZeneca) and the Salk Institute (Sanofi-Aventis) are a few who have inked deals within the last couple of years. While many of these academic institutions are wading for the first time into this style of arrangement, the Scripps Research Institute has managed large strategic industry alliances for the better part of the last three decades and currently counts Pfizer and Novartis as major corporate partners.

At Scripps, these deals have evolved to include research funding and IP licensing components. They provide important benefit to both Scripps and our corporate partners. Scripps gains valuable research and discretionary funds, used to seed early research projects and recruit/retain top faculty, in addition to enabling access to expertise and infrastructure more prevalent in a pharmaceutical company (e.g. specialized animal models). In turn, our partners gain access to the kind of transformative research that is uniquely enabled in academia.

Despite the obvious benefits, broad research alliances such as these can also present challenges-inadequate communication, misalignment of incentives and a community perception that the academic partner is inaccessible to other potential industrial collaborators. These challenges need to be managed properly if both parties are to realize full value from the relationship.

Broad alliances involve a large amount of information exchange, the sheer volume of which necessitates regular attention. Systematic, frequent and open communication … Next Page »

Single PageCurrently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

3 responses to “How To Keep Academic/Big Pharma Alliances from Going off the Rails”

  1. pipetodevnull says:

    IMHO part of the current Reaganization of science. Perhaps inevitable, sad nonetheless.

  2. anon says:

    Thanks for a wasting 5 min of my time with a poorly written article that contains no substance.